Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4% to ...

Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. Participating in the call this morning are Jay ...

IDEXX Laboratories is a leader in animal diagnostics, boasting strong recurring revenue and nearly 50% stock gains year-to-date. IDXX's innovation pipeline, robust cash position, and global reach ...

Earnings call IDEXX reported Q4 2025 organic revenue growth of 12%, with EPS up 17% YoY to $3.08 and operating margin expansion to 60.3%. Full-year organic revenue rose 10%, and EPS reached $13.08, up ...

Seilern sold 70,900 shares of IDEXX Laboratories; estimated transaction value of approximately $43.03 million. The sale represents a 3.11% change relative to the fund’s 13F AUM. Post-trade holding: ...

Idexx reported fourth-quarter results that included organic revenue growth of 12% and adjusted earnings growth of 17% supported by operating margin improvement of 120 basis points year over year.

The Investment Committee gives you their top stocks to watch for the second half. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to ...